Braden Michael Leonard Buys 13,167 Shares of Talis Biomedical Co. (NASDAQ:TLIS) Stock

Talis Biomedical Co. (NASDAQ:TLIS) major shareholder Braden Michael Leonard acquired 13,167 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were acquired at an average price of $3.90 per share, with a total value of $51,351.30. Following the completion of the purchase, the insider now owns 216,736 shares of the company’s stock, valued at $845,270.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Wednesday, August 28th, Braden Michael Leonard bought 1,215 shares of Talis Biomedical stock. The shares were acquired at an average price of $3.96 per share, for a total transaction of $4,811.40.

Talis Biomedical Price Performance

NASDAQ TLIS traded up $0.21 during trading hours on Wednesday, hitting $4.10. The company had a trading volume of 2,770 shares, compared to its average volume of 12,446. The firm’s 50 day moving average is $7.28 and its 200 day moving average is $8.24. Talis Biomedical Co. has a fifty-two week low of $3.42 and a fifty-two week high of $9.60. The company has a market capitalization of $7.46 million, a price-to-earnings ratio of -0.12 and a beta of 1.68.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.